Navigation Links
Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer

REDWOOD CITY, Calif., March 2 /PRNewswire/ -- Pearl Therapeutics, a biopharmaceutical company developing products for the treatment of widely prevalent respiratory diseases, announced today the appointment of Perry Karsen as Chief Executive Officer.

"We are delighted to attract a corporate leader with such an outstanding record of achievement," stated James W. Young, Ph.D., Venture Partner at 5AM Ventures and Executive Chairman of Pearl Therapeutics. "The Pearl team has made exceptional progress on the development of its portfolio of novel products to treat respiratory diseases and we are confident that Perry, with his extensive background and experience, will contribute significantly to the further success of the company."

"I am truly excited to join the seasoned group of professionals at Pearl working to bring new, high quality therapies to patients with serious respiratory diseases," stated Mr. Karsen. "Pearl's line of products will offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing therapeutics to achieve better clinical outcomes."

As Pearl Therapeutics' new Chief Executive Officer, Perry Karsen brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Perry served as Regional President, Asia/Pacific and Head of Worldwide Business Development at Celgene Corporation, and was also a member of the company's Management, Operating, and Product Development Committees. Previously, Perry held the position of Senior Vice President of Business Development at Human Genome Sciences, and prior to that was a General Partner at Pequot Ventures focusing on venture investments in emerging biopharmaceutical and medical device companies. Earlier, he was Vice President, Corporate Development at Bristol-Myers Squibb and Senior Vice President, Marketing at Zimmer, Inc. Perry was a Director in the Business Development department at Genentech, Inc. and Representative Director of Genentech Japan. Perry began his career with Abbott and over the course of eleven years served in roles of increasing responsibility in product development, international business management, domestic and international marketing, and licensing. He has a Masters of Management degree from Northwestern University's Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana.

About Pearl Therapeutics, Inc.

Pearl is developing a portfolio of meaningfully differentiated products to treat respiratory diseases including COPD and asthma. Using its proprietary particle technology, formulation expertise, and unparalleled development experience, Pearl is rapidly advancing a pipeline of products that will offer alternatives to patients and healthcare professionals, ones that better meet their needs, and intend to improve disease management and quality of life.

Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and 5AM Ventures.

    Pearl Therapeutics
    Adrian Smith

    For Pearl Therapeutics
    Jennifer Larson

SOURCE Pearl Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Secures $8 Million in Debt Financing
2. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
3. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
4. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
5. String of fullerene pearls
6. Pearl Therapeutics Raises $15.5 Million in Private Financing
7. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
8. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
9. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
11. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):